David Loury

3.3k total citations · 1 hit paper
31 papers, 2.6k citations indexed

About

David Loury is a scholar working on Molecular Biology, Cancer Research and Hematology. According to data from OpenAlex, David Loury has authored 31 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 9 papers in Cancer Research and 8 papers in Hematology. Recurrent topics in David Loury's work include Carcinogens and Genotoxicity Assessment (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Antimicrobial Peptides and Activities (4 papers). David Loury is often cited by papers focused on Carcinogens and Genotoxicity Assessment (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Antimicrobial Peptides and Activities (4 papers). David Loury collaborates with scholars based in United States, Belgium and France. David Loury's co-authors include Joseph J. Buggy, Richard A. Miller, Mint Sirisawad, Betty Chang, Douglas H. Thamm, Lee Honigberg, Ashley M. Smith, Erik Verner, Zhengying Pan and John C. Fiddes and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

David Loury

31 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

2010 1.2k citations Mint Sirisawad, David Loury et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Loury United States	18	1.0k	980	702	551	433	31	2.6k
Yumi Aoyama Japan	30	942 0.9×	745 0.8×	1.1k 1.6×	503 0.9×	71 0.2×	167	3.1k
Bruce U. Wintroub United States	31	830 0.8×	579 0.6×	691 1.0×	1.5k 2.7×	32 0.1×	57	3.8k
Martin E. Dowty United States	24	790 0.8×	270 0.3×	160 0.2×	750 1.4×	16 0.0×	57	3.0k
J Bréard France	17	756 0.7×	299 0.3×	234 0.3×	1.3k 2.4×	30 0.1×	22	2.9k
M. Lopez France	24	618 0.6×	639 0.7×	87 0.1×	513 0.9×	28 0.1×	81	2.3k
Brigitte Bauvois France	30	1.3k 1.3×	189 0.2×	161 0.2×	444 0.8×	36 0.1×	90	3.0k
Katsuhisa Kogawa Japan	23	735 0.7×	181 0.2×	341 0.5×	274 0.5×	29 0.1×	67	2.0k
Stacie A. Dalrymple United States	18	1.0k 1.0×	344 0.4×	253 0.4×	892 1.6×	30 0.1×	24	2.5k
G Stingl Austria	20	341 0.3×	269 0.3×	656 0.9×	2.0k 3.6×	19 0.0×	32	3.2k
Jens Oliver Funk Germany	28	1.2k 1.2×	130 0.1×	270 0.4×	450 0.8×	28 0.1×	44	2.7k

Countries citing papers authored by David Loury

Since Specialization

Citations

This map shows the geographic impact of David Loury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Loury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Loury more than expected).

Fields of papers citing papers by David Loury

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Loury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Loury. The network helps show where David Loury may publish in the future.

Co-authorship network of co-authors of David Loury

This figure shows the co-authorship network connecting the top 25 collaborators of David Loury. A scholar is included among the top collaborators of David Loury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Loury. David Loury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jong, Jan de, Juthamas Sukbuntherng, Donna Skee, et al.. (2015). The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemotherapy and Pharmacology. 75(5). 907–916. 60 indexed citations

Sukbuntherng, Juthamas, David Loury, Jan de Jong, et al.. (2014). Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemotherapy and Pharmacology. 75(1). 111–121. 49 indexed citations

Fouliard, Sylvain, Sriram Balasubramanian, David Loury, et al.. (2013). Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. European Journal of Cancer. 49(13). 2791–2797. 23 indexed citations

Loury, David, Juthamas Sukbuntherng, Fong Clow, Danelle F. James, & Lori Kunkel. (2013). Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy.. Journal of Clinical Oncology. 31(15_suppl). 7057–7057. 6 indexed citations

Fowler, Nathan, Sonali M. Smith, Thomas E. Boyd, et al.. (2010). The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study. Blood. 116(21). 964–964. 36 indexed citations

Undevia, Samir D., Linda Janisch, Richard L. Schilsky, et al.. (2008). Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781. Journal of Clinical Oncology. 26(15_suppl). 14514–14514. 14 indexed citations

Loury, David, et al.. (2007). PCI-27483, a small molecule inhibitor of factor VIIa, inhibits tumor growth in vivo.. Molecular Cancer Therapeutics. 6. 1 indexed citations

Watkins, William J., Lee S. Chong, Aesop Cho, et al.. (2007). Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimization. Bioorganic & Medicinal Chemistry Letters. 17(10). 2802–2806. 21 indexed citations

Chen, Jie, Timothy J. Falla, Hongjian Liu, et al.. (2000). Development of protegrins for the treatment and prevention of oral mucositis: Structure-activity relationships of synthetic protegrin analogues. Biopolymers. 55(1). 88–98. 139 indexed citations

10.

Loury, David, et al.. (1999). Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology. 87(5). 544–551. 46 indexed citations

11.

Hegde, Sharath S., Agnès Choppin, D BONHAUS, et al.. (1997). Functional role of M₂ and M₃ muscarinic receptors in the urinary bladder of rats in vitro and in vivo. British Journal of Pharmacology. 120(8). 1409–1418. 256 indexed citations

12.

Wong, Erik H.F., Robin D. Clark, Edward Leung, et al.. (1995). The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT₃ receptors, in vitro. British Journal of Pharmacology. 114(4). 851–859. 150 indexed citations

13.

Loury, David, Tracey Smith-Oliver, & Byron E. Butterworth. (1987). Assessment of the covalent binding potential of 2,2,4-trimethylpentane to rat α2u-globulin. Toxicology and Applied Pharmacology. 88(1). 44–56. 14 indexed citations

14.

Butterworth, Byron E., David Loury, Tracey Smith-Oliver, & Russell C. Cattley. (1987). The Potential Role of Chemically Induced Hyperplasia in the Carcinogenic Activity of the Hypolipidemic Carcinogens. Toxicology and Industrial Health. 3(2). 129–149. 44 indexed citations

15.

Loury, David. (1986). Assessment of unscheduled and replicative DNA synthesis in hepatocytes treated in vivo and in vitro with unleaded gasoline or 2,2,4-trimethylpentane*1. Toxicology and Applied Pharmacology. 85(1). 11–23. 33 indexed citations

16.

Loury, David, Norman Y. Kado, & James L. Byard. (1985). Enhancement of hepatocellular genotoxicity of several mutagens from amino acid pyrolysates and broiled foods following ethanol pretreatment. Food and Chemical Toxicology. 23(7). 661–667. 9 indexed citations

17.

Loury, David & James L. Byard. (1985). Genotoxicity of the cooked‐food mutagens IQ and MeIQ in primary cultures of rat, hamster, and guinea pig hepatocytes. Environmental Mutagenesis. 7(2). 245–254. 11 indexed citations

18.

Loury, David, Dennis P. H. Hsieh, & James L. Byard. (1984). The effect of phenobarbital pretreatment on the metabolism, covalent binding, and cytotoxicity of aflatoxin B₁in primary cultures of rat hepatocytes. Journal of Toxicology and Environmental Health. 13(1). 145–159. 17 indexed citations

19.

Loury, David, James L. Byard, & Takayuki Shibamoto. (1984). Genotoxicity of N-nitrosothiazolidine in microbial and hepatocellular test systems. Food and Chemical Toxicology. 22(12). 1013–1014. 3 indexed citations

20.

Loury, David & James L. Byard. (1983). Aroclor 1254 pretreatment enhances the DNA repair response to amino acid pyrolysate mutagens in primary cultures of rat hepatocytes. Cancer Letters. 20(3). 283–290. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact